Medical management of ankylosing spondylitis
- 1 January 2008
- journal article
- review article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 24 (1) , E4
Abstract
✓ In the following literature review the authors consider the available evidence for the medical management of patients with ankylosing spondylitis (AS), and they critically assess current treatment guidelines. Medical therapy for axial disease in AS emphasizes improvement in patients' pain and overall function. First-line treatments include individualized physical therapy and nonsteroidal antiinflammatory drugs (NSAIDs) in conjunction with gastroprotective therapy. After an adequate trial of therapy with two NSAIDs exceeding 3 months or limited by medication toxicity, the patient may undergo tumor necrosis factor–α blockade therapy. Response should occur within 6–12 weeks, and patients must undergo tuberculosis screening. Evidence does not currently support the use of disease modifying antirheumatic drugs, corticosteroids, or radiotherapy in AS.Keywords
This publication has 12 references indexed in Scilit:
- Ankylosing spondylitisThe Lancet, 2007
- ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitisRheumatology International, 2005
- Kosten und Nutzen eines Schulungsprogramms f r Patienten mit Spondylitis ankylosans in der station ren RehabilitationZeitschrift für Rheumatologie, 2003
- International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2003
- Medication toxicity among patients with ankylosing spondylitisArthritis Care & Research, 2002
- A six‐month randomized, controlled, double‐blind, dose‐response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitisArthritis & Rheumatism, 2002
- Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitisArthritis & Rheumatism, 1995
- Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trialArthritis & Rheumatism, 1993